CMIC HOLDINGS Co., Ltd. (the “Company”) hereby announces the following revisions to the forecasts of the full-year consolidated results announced on November 8, 2022 for the fiscal year ending September 30, 2023.
Notes
1．Revision of FY2022 Full-year Forecast (October 1, 2022 to September 30, 2023)
| Net sales | Operating Profit | Ordinary Profit | Profit attributable to owners of parent |
Earnings per share |
|
|
Previous forecast
(A) |
Millions of yen 95,000 |
Millions of yen 5,000 |
Millions of yen 4,700 |
Millions of yen 2,900 |
Yen 165.23 |
| Current revised forecast(B) |
105,000 | 10,300 | 9,000 | 7,300 | 420.42 |
| Increase (B-A) | 10,000 | 5,300 | 4,300 | 4,400 | － |
| Rate of change (%) | 10.5 | 106.0 | 91.5 | 151.7 | － |
|
(Reference)
Results for the previous fiscal year (FY2022) |
108,461 | 11,845 | 13,450 | 8,387 | 469.44 |
(Reasons for amendment)
Taking into account the results of the first half of the current fiscal year, the forecast for the fiscal year ending September 30, 2023 incorporates the forecast for matters affecting the first half of the fiscal year based on information available at this time.
In the second quarter consolidated cumulative period, we substantially exceeded our initial forecast due to a significant increase in municipal support services related to COVID-19 and a gain on sale of investment securities of 3,349 million yen recorded as an extraordinary income.
As for matters that will affect business results in the second half of the fiscal year, as announced in the “Notice of Change of CDMO Business Subsidiary and Notice of Strategic Business Alliance with Dai Nippon Printing Co., Ltd.” dated April 17, 2023, some subsidiaries in the CDMO (Contract Development and Manufacturing Organization) business of our Pharmaceuticals Solutions are expected to become equity-method affiliates from June 2023.
As for the impact of COVID-19, the shift of the classification of COVID-19 to category 5 under the Infectious Diseases Control Law effective May 8, 2023 is expected to reduce the number of vaccination projects that have driven our performance in the first half of the current fiscal year.
Further, the situation in Ukraine will not have a significant direct impact on our operations in Russia and Ukraine, as we do not have any offices in either country, but there will be an impact on our profits due to higher energy and logistics costs, which we have incorporated into our forecast.
Based on the above, we have revised upward our full-year forecasts for the fiscal year ending September 30, 2023, to net sales of ¥ 105,000 million, operating profit of ¥ 10,300 million, ordinary profit of ¥ 9,000 million, and profit attributable to owners of parent of ¥7,300 million, respectively.
PDF Click Here to Read Now
